TR200002751T2 - Sistemik etkisi olan lokal hormon terkibi - Google Patents
Sistemik etkisi olan lokal hormon terkibiInfo
- Publication number
- TR200002751T2 TR200002751T2 TR2000/02751T TR200002751T TR200002751T2 TR 200002751 T2 TR200002751 T2 TR 200002751T2 TR 2000/02751 T TR2000/02751 T TR 2000/02751T TR 200002751 T TR200002751 T TR 200002751T TR 200002751 T2 TR200002751 T2 TR 200002751T2
- Authority
- TR
- Turkey
- Prior art keywords
- hormone composition
- women
- active substance
- systemic effects
- progesterone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Abstract
Bu bulus kemoterapi alaniyla ve özellikle cilde uygulanacak yeni galenik formlarin gelistirilmesiyle ilgilidir. Özellikle, menopoz öncesi dönemdeki kadinlarda progesteron eksikliginin düzeltilmesi ve menopoz dönemindeki kadinlarda hormon yenilenmesi için bir jel ve/veya bir film gibi bir farmasötik formun üretilmesi için aktif madde olarak 19-nor progesterone'dan elde edilen bir progestogen, bu aktif maddenin sistemik geçisi için solübilizasyon maddesi, bir absorpsiyon artirici, bir film olusturucu ve bir jellestirici madde arasindan seçilen bir tasiyicinin uygun eksipiyanlarla kombinasyon veya karisim olarak içermesiyle karakterize edilen, sistemik etkili bir topikal hormon terkibiyle ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9803533A FR2776191B1 (fr) | 1998-03-23 | 1998-03-23 | Composition hormonale topique a effet systemique |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200002751T2 true TR200002751T2 (tr) | 2000-12-21 |
Family
ID=9524367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2000/02751T TR200002751T2 (tr) | 1998-03-23 | 1999-03-23 | Sistemik etkisi olan lokal hormon terkibi |
Country Status (29)
Country | Link |
---|---|
US (1) | US20080227763A1 (tr) |
EP (1) | EP1066030B1 (tr) |
JP (1) | JP4579411B2 (tr) |
KR (1) | KR100681322B1 (tr) |
CN (1) | CN1161102C (tr) |
AP (1) | AP1343A (tr) |
AT (1) | ATE353626T1 (tr) |
AU (1) | AU754490B2 (tr) |
BR (1) | BR9909027A (tr) |
CA (1) | CA2324904C (tr) |
CY (1) | CY1106463T1 (tr) |
CZ (1) | CZ300484B6 (tr) |
DE (1) | DE69935135T2 (tr) |
DK (1) | DK1066030T3 (tr) |
ES (1) | ES2283106T3 (tr) |
FR (1) | FR2776191B1 (tr) |
HK (1) | HK1038184A1 (tr) |
HU (1) | HU228863B1 (tr) |
ID (1) | ID27988A (tr) |
IL (1) | IL138607A0 (tr) |
NO (1) | NO331222B1 (tr) |
NZ (1) | NZ507201A (tr) |
OA (1) | OA11489A (tr) |
PL (1) | PL204210B1 (tr) |
PT (1) | PT1066030E (tr) |
RU (1) | RU2215520C2 (tr) |
TR (1) | TR200002751T2 (tr) |
WO (1) | WO1999048477A1 (tr) |
ZA (1) | ZA200005785B (tr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29270A (id) * | 1998-11-20 | 2001-08-16 | Rtp Pharma Inc | Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar |
WO2001030356A1 (fr) * | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
DE10008128A1 (de) * | 2000-02-22 | 2001-08-23 | Bayer Ag | Endoparasitizide Mittel |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
US7803392B2 (en) | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
US7005557B2 (en) | 2001-07-03 | 2006-02-28 | The Procter & Gamble Company | Film-forming compositions for protecting skin from body fluids and articles made therefrom |
GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
DE10146541A1 (de) * | 2001-09-21 | 2003-04-17 | Kade Pharma Fab Gmbh | Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung |
DK1670433T3 (da) | 2003-10-10 | 2012-03-12 | Ferring Bv | Transdermal farmaceutisk formulering til mindskelse af hudrester |
WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
US7772213B2 (en) | 2006-07-27 | 2010-08-10 | Nathan Strick | Composition for the treatment of inflammatory conditions |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
MX365818B (es) | 2011-11-23 | 2019-05-30 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2742932A1 (en) * | 2012-12-17 | 2014-06-18 | Laboratorios Ojer Pharma S.L. | Gel compositions |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2020161771A1 (ja) * | 2019-02-04 | 2020-08-13 | マルホ株式会社 | 皮膚用組成物 |
GB2597637A (en) * | 2020-06-02 | 2022-02-09 | Surfachem Ltd | Sanitiser composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2180690T3 (es) * | 1990-06-01 | 2003-02-16 | Population Council Inc | Preparacion de composiciones que comprenden st1435 para aplicacion topica. |
FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
JPH05148146A (ja) * | 1991-06-20 | 1993-06-15 | Terumo Corp | 水溶性ゲル外用剤 |
JP2960832B2 (ja) * | 1992-05-08 | 1999-10-12 | ペルマテック テクノロジー アクチェンゲゼルシャフト | エストラジオールの投与システム |
FR2695826B1 (fr) * | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
DE4309830C1 (de) * | 1993-03-26 | 1994-05-05 | Lohmann Therapie Syst Lts | Wirkstoffpflaster für die Abgabe von Estradiol an die Haut |
IL105600A (en) * | 1993-05-04 | 1999-12-31 | Allon Blank | Pharmaceutical and cosmetic compositions with increased rate of transdermal penetration and antioxidation protection against degradation containing derivatives of thioglycolic and mercaptopropionic acids some such novel compounds and their use |
EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
EP0785212A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New 19-nor-pregnene derivatives |
JP4346696B2 (ja) * | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | 経皮治療用装置 |
IT1283102B1 (it) * | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
-
1998
- 1998-03-23 FR FR9803533A patent/FR2776191B1/fr not_active Expired - Fee Related
-
1999
- 1999-03-23 TR TR2000/02751T patent/TR200002751T2/tr unknown
- 1999-03-23 CZ CZ20003471A patent/CZ300484B6/cs not_active IP Right Cessation
- 1999-03-23 AP APAP/P/2000/001948A patent/AP1343A/en active
- 1999-03-23 RU RU2000126490/15A patent/RU2215520C2/ru not_active IP Right Cessation
- 1999-03-23 AU AU28451/99A patent/AU754490B2/en not_active Ceased
- 1999-03-23 PL PL343256A patent/PL204210B1/pl unknown
- 1999-03-23 KR KR1020007010569A patent/KR100681322B1/ko not_active IP Right Cessation
- 1999-03-23 NZ NZ507201A patent/NZ507201A/en not_active IP Right Cessation
- 1999-03-23 WO PCT/FR1999/000680 patent/WO1999048477A1/fr active IP Right Grant
- 1999-03-23 EP EP99909078A patent/EP1066030B1/fr not_active Expired - Lifetime
- 1999-03-23 ES ES99909078T patent/ES2283106T3/es not_active Expired - Lifetime
- 1999-03-23 DK DK99909078T patent/DK1066030T3/da active
- 1999-03-23 HU HU0101579A patent/HU228863B1/hu not_active IP Right Cessation
- 1999-03-23 BR BR9909027-9A patent/BR9909027A/pt not_active IP Right Cessation
- 1999-03-23 DE DE69935135T patent/DE69935135T2/de not_active Expired - Lifetime
- 1999-03-23 IL IL13860799A patent/IL138607A0/xx unknown
- 1999-03-23 CA CA002324904A patent/CA2324904C/fr not_active Expired - Fee Related
- 1999-03-23 CN CNB998064122A patent/CN1161102C/zh not_active Expired - Fee Related
- 1999-03-23 ID IDW20002123A patent/ID27988A/id unknown
- 1999-03-23 JP JP2000537527A patent/JP4579411B2/ja not_active Expired - Fee Related
- 1999-03-23 AT AT99909078T patent/ATE353626T1/de active
- 1999-03-23 PT PT99909078T patent/PT1066030E/pt unknown
-
2000
- 2000-09-22 OA OA1200000259A patent/OA11489A/fr unknown
- 2000-09-22 NO NO20004745A patent/NO331222B1/no not_active IP Right Cessation
- 2000-10-18 ZA ZA200005785A patent/ZA200005785B/xx unknown
-
2001
- 2001-12-13 HK HK01108759A patent/HK1038184A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 CY CY20071100563T patent/CY1106463T1/el unknown
-
2008
- 2008-03-20 US US12/077,665 patent/US20080227763A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200002751T2 (tr) | Sistemik etkisi olan lokal hormon terkibi | |
DZ3221A1 (fr) | Nouvelles compositions estro-progestatives topiques a effet systemique | |
ATE75947T1 (de) | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. | |
MEP38008A (en) | Drospirenone for hormone replacement therapy | |
UY24806A1 (es) | Procedimiento para la preparación de composiciones farmacéuticas para la entrega sostenida de péptidos | |
Willemse et al. | Altered Leydig cell function in patients with testicular cancer: evidence for a bilateral testicular defect | |
MXPA03001859A (es) | Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados. | |
GB1444989A (en) | Steroid formulation fluid reaction machines and erosion indicators therefor | |
GB1472308A (en) | Steroidal topical cream base | |
Ojanotko-Harri et al. | Immunohistochemical detection of androgen receptors in human oral mucosa | |
ES2074030A1 (es) | Composiciones portadoras, autocalentadoras y aplicables en terapeutica por via topica. | |
HUP9904508A2 (hu) | Egy ösztrogén vegyületet és egy progesztatív vegyületet tartalmazó hormonkészítmény | |
CO4960657A1 (es) | Composicion farmaceutica | |
GB1467947A (en) | Steroid compositions and processes for their preparation | |
GB1254534A (en) | Improvements in or relating to treating means for wounds | |
DE59002738D1 (de) | Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen. | |
JPS52136157A (en) | Preparation of steroid 17-esters | |
GB1133800A (en) | Pharmaceutical compositions | |
IE34308B1 (en) | 11beta,13beta dialkylgona-1,3,5(10)-trien-3-ol 3-cycloalkyl ethers | |
GB1430223A (en) | Anti-inflammatory composition comprising steroids | |
Bojar et al. | The Endocrine Background of Human Renal Cell Carcinoma: V. Binding of the Highly Potent Androgen Methyltrienolone (R 1881) by Tumour Cytosol | |
Harri et al. | 63. Progesterone metabolism in healthy and inflamed female gingiva | |
EA200300322A1 (ru) | 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции | |
Schöneshöfer et al. | 66. Inhibition of total corticosteroid secretion by metyrapone in man | |
Mayer et al. | 104. Chromatographic and immunological characteristics of corticosteroid binder IB |